Skip to main content
SpringerLink
Log in

Clinical Use of the Calcium-Binding S100B Protein

  • Protocol
  • First Online:
Calcium-Binding Proteins and RAGE

Part of the book series: Methods in Molecular Biology ((MIMB,volume 963))

Abstract

S100B is a calcium-binding protein most abundant in neuronal tissue. It is expressed in glia cells and Schwann cells and exerts both intra- and extracellular effects. Depending on the concentration, secreted S100B exerts either trophic or toxic effects. Its functions have been extensively studied but are still not fully understood. It can be measured in cerebrospinal fluid and blood, and increased S100B level in blood can be seen after, e.g., traumatic brain injury, certain neurodegenerative disorders and malignant melanoma.

This chapter provides a short background of protein S100B, commercially available methods of analysis, and its clinical use.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Moore BW (1965) A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 19:739–744

    Article  PubMed  CAS  Google Scholar 

  2. Isobe T, Okuyama T (1981) The amino-acid sequence of the alpha subunit in bovine brain S-100a protein. Eur J Biochem 116:79–86

    Article  PubMed  CAS  Google Scholar 

  3. Marenholz I, Heizmann CW, Fritz G (2004) S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 322:1111–1122

    Article  PubMed  CAS  Google Scholar 

  4. Marenholz I, Lovering RC, Heizmann CW (2006) An update of the S100 nomenclature. Biochim Biophys Acta 1763:1282–1283

    Article  PubMed  CAS  Google Scholar 

  5. Kizawa K, Takahara H, Unno M, Heizmann CW (2011) S100 and S100 fused-type protein families in epidermal maturation with special focus on S100A3 in mammalian hair cuticles. Biochimie 93:2038–2047

    Article  PubMed  CAS  Google Scholar 

  6. Ostendorp T, Leclerc E, Galichet A, Koch M, Demling N, Weigle B et al (2007) Structural and functional insights into RAGE activation by multimeric S100B. EMBO J 26:3868–3878

    Article  PubMed  CAS  Google Scholar 

  7. Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS (2006) Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 396:201–214

    Article  PubMed  CAS  Google Scholar 

  8. Donato R, Heizmann CW (2010) S100B protein in the nervous system and cardiovascular apparatus in normal and pathological conditions. Cardiovasc Psychiatry Neurol 2010:929712

    PubMed  Google Scholar 

  9. Harpio R, Einarsson R (2004) S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 37:512–518

    Article  PubMed  CAS  Google Scholar 

  10. Haimoto H, Hosoda S, Kato K (1987) Differential distribution of immunoreactive S100-alpha and S100-beta proteins in normal nonnervous human tissues. Lab Invest 57:489–498

    PubMed  CAS  Google Scholar 

  11. Wiesmann M, Missler U, Gottmann D, Gehring S (1998) Plasma S-100b protein concentration in healthy adults is age- and sex-independent. Clin Chem 44:1056–1058

    PubMed  CAS  Google Scholar 

  12. Marchi N, Rasmussen P, Kapural M, Fazio V, Kight K, Mayberg MR et al (2003) Peripheral markers of brain damage and blood-brain barrier dysfunction. Restor Neurol Neurosci 21:109–121

    PubMed  CAS  Google Scholar 

  13. Jonsson H, Johnsson P, Hoglund P, Alling C, Blomquist S (2000) Elimination of S100B and renal function after cardiac surgery. J Cardiothorac Vasc Anesth 14:698–701

    Article  PubMed  CAS  Google Scholar 

  14. Blomquist S, Johnsson P, Luhrs C, Malmkvist G, Solem JO, Alling C et al (1997) The appearance of S-100 protein in serum during and immediately after cardiopulmonary bypass surgery: a possible marker for cerebral injury. J Cardiothorac Vasc Anesth 11:699–703

    Article  PubMed  CAS  Google Scholar 

  15. Raabe A, Kopetsch O, Gross U, Zimmermann M, Gebhart P (2003) Measurements of serum S-100B protein: effects of storage time and temperature on pre-analytical stability. Clin Chem Lab Med 41:700–703

    Article  PubMed  CAS  Google Scholar 

  16. Hallen M, Carlhed R, Karlsson M, Hallgren T, Bergenheim M (2008) A comparison of two different assays for determining S-100B in serum and urine. Clin Chem Lab Med 46:1025–1029

    Article  PubMed  CAS  Google Scholar 

  17. Raabe A, Menon DK, Gupta S, Czosnyka M, Pickard JD (1998) Jugular venous and arterial concentrations of serum S-100B protein in patients with severe head injury: a pilot study. J Neurol Neurosurg Psychiatry 65:930–932

    Article  PubMed  CAS  Google Scholar 

  18. Kunihara T, Shiiya N, Bin L, Yasuda K (2006) Arterio-jugular differences in serum S-100beta proteins in patients receiving selective cerebral perfusion. Surg Today 36:6–11

    Article  PubMed  CAS  Google Scholar 

  19. Muller K, Townend W, Biasca N, Unden J, Waterloo K, Romner B et al (2007) S100B serum level predicts computed tomography findings after minor head injury. J Trauma 62:1452–1456

    Article  PubMed  CAS  Google Scholar 

  20. Astrand R, Romner B, Lanke J, Unden J (2011) Reference values for venous and capillary S100B in children. Clin Chim Acta 412:2190–2193

    Article  PubMed  CAS  Google Scholar 

  21. Ingebrigtsen T, Romner B, Kock-Jensen C (2000) Scandinavian guidelines for initial management of minimal, mild, and moderate head injuries. The Scandinavian Neurotrauma Committee. J Trauma 48:760–766

    Article  PubMed  CAS  Google Scholar 

  22. af Geijerstam JL, Britton M (2003) Mild head injury—mortality and complication rate: meta-analysis of findings in a systematic literature review. Acta Neurochir (Wien) 145:843–850, discussion 850

    Article  Google Scholar 

  23. Unden J, Bellner J, Astrand R, Romner B (2005) Serum S100B levels in patients with epidural haematomas. Br J Neurosurg 19:43–45

    Article  PubMed  CAS  Google Scholar 

  24. Unden J, Romner B (2009) A new objective method for CT triage after minor head injury—serum S100B. Scand J Clin Lab Invest 69:13–17

    Article  PubMed  CAS  Google Scholar 

  25. Biberthaler P, Mussack T, Wiedemann E, Gilg T, Soyka M, Koller G et al (2001) Elevated serum levels of S-100B reflect the extent of brain injury in alcohol intoxicated patients after mild head trauma. Shock 16:97–101

    Article  PubMed  CAS  Google Scholar 

  26. Biberthaler P, Mussack T, Wiedemann E, Kanz KG, Koelsch M, Gippner-Steppert C et al (2001) Evaluation of S-100b as a specific marker for neuronal damage due to minor head trauma. World J Surg 25:93–97

    Article  PubMed  CAS  Google Scholar 

  27. Ingebrigtsen T, Romner B, Marup-Jensen S, Dons M, Lundqvist C, Bellner J et al (2000) The clinical value of serum S-100 protein measurements in minor head injury: a Scandinavian multicentre study. Brain Inj 14:1047–1055

    Article  PubMed  CAS  Google Scholar 

  28. Mussack T, Biberthaler P, Kanz KG, Heckl U, Gruber R, Linsenmaier U et al (2002) Immediate S-100B and neuron-specific enolase plasma measurements for rapid evaluation of primary brain damage in alcohol-intoxicated, minor head-injured patients. Shock 18:395–400

    Article  PubMed  Google Scholar 

  29. Poli-de-Figueiredo LF, Biberthaler P, Simao Filho C, Hauser C, Mutschler W, Jochum M (2006) Measurement of S-100B for risk classification of victims sustaining minor head injury—first pilot study in Brazil. Clinics (Sao Paulo) 61:41–46

    Article  Google Scholar 

  30. Unden J, Romner B (2010) Can low serum levels of S100B predict normal CT findings after minor head injury in adults?: an evidence-based review and meta-analysis. J Head Trauma Rehabil 25:228–240

    Article  PubMed  Google Scholar 

  31. Kleine TO, Benes L, Zofel P (2003) Studies of the brain specificity of S100B and neuron-specific enolase (NSE) in blood serum of acute care patients. Brain Res Bull 61:265–279

    Article  PubMed  CAS  Google Scholar 

  32. Unden J, Bellner J, Eneroth M, Alling C, Ingebrigtsen T, Romner B (2005) Raised serum S100B levels after acute bone fractures without cerebral injury. J Trauma 58:59–61

    Article  PubMed  Google Scholar 

  33. Anderson RE, Hansson LO, Nilsson O, Dijlai-Merzoug R, Settergren G (2001) High serum S100B levels for trauma patients without head injuries. Neurosurgery 48:1255–1258, discussion 1258–1260

    PubMed  CAS  Google Scholar 

  34. Biberthaler P, Mussack T, Wiedemann E, Kanz KG, Gilg T, Gippner-Steppert C et al (2000) Influence of alcohol exposure on S-100b serum levels. Acta Neurochir Suppl 76:177–179

    PubMed  CAS  Google Scholar 

  35. Biberthaler P, Linsenmeier U, Pfeifer KJ, Kroetz M, Mussack T, Kanz KG et al (2006) Serum S-100B concentration provides additional information fot the indication of computed tomography in patients after minor head injury: a prospective multicenter study. Shock 25:446–453

    Article  PubMed  CAS  Google Scholar 

  36. Zongo D, Ribereau-Gayon R, Masson F, Laborey M, Contrand B, Salmi LR et al (2011) S100-B protein as a screening tool for the early assessment of minor head injury. Ann Emerg Med 59:209–218

    Article  PubMed  Google Scholar 

  37. Raabe A, Grolms C, Seifert V (1999) Serum markers of brain damage and outcome prediction in patients after severe head injury. Br J Neurosurg 13:56–59

    Article  PubMed  CAS  Google Scholar 

  38. Nylen K, Ost M, Csajbok LZ, Nilsson I, Blennow K, Nellgard B et al (2006) Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci 240:85–91

    Article  PubMed  CAS  Google Scholar 

  39. da Rocha AB, Schneider RF, de Freitas GR, Andre C, Grivicich I, Zanoni C et al (2006) Role of serum S100B as a predictive marker of fatal outcome following isolated severe head injury or multitrauma in males. Clin Chem Lab Med 44:1234–1242

    PubMed  Google Scholar 

  40. Wiesmann M, Steinmeier E, Magerkurth O, Linn J, Gottmann D, Missler U (2010) Outcome prediction in traumatic brain injury: comparison of neurological status, CT findings, and blood levels of S100B and GFAP. Acta Neurol Scand 121:178–185

    Article  PubMed  CAS  Google Scholar 

  41. Vos PE, Jacobs B, Andriessen TM, Lamers KJ, Borm GF, Beems T et al (2010) GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology 75:1786–1793

    Article  PubMed  CAS  Google Scholar 

  42. Raabe A, Grolms C, Sorge O, Zimmermann M, Seifert V (1999) Serum S-100B protein in severe head injury. Neurosurgery 45:477–483

    Article  PubMed  CAS  Google Scholar 

  43. Woertgen C, Rothoerl RD, Metz C, Brawanski A (1999) Comparison of clinical, radiologic, and serum marker as prognostic factors after severe head injury. J Trauma 47:1126–1130

    Article  PubMed  CAS  Google Scholar 

  44. Nylen K, Ost M, Csajbok LZ, Nilsson I, Hall C, Blennow K et al (2008) Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. Acta Neurochir (Wien) 150:221–227, discussion 227

    Article  CAS  Google Scholar 

  45. Bohmer AE, Oses JP, Schmidt AP, Peron CS, Krebs CL, Oppitz PP et al (2011) Neuron-specific enolase, S100B, and glial fibrillary acidic protein levels as outcome predictors in patients with severe traumatic brain injury. Neurosurgery 68:1624–1631

    Article  PubMed  Google Scholar 

  46. Dimopoulou I, Korfias S, Dafni U, Anthi A, Psachoulia C, Jullien G et al (2003) Protein S-100b serum levels in trauma-induced brain death. Neurology 60:947–951

    Article  PubMed  CAS  Google Scholar 

  47. Bellander BM, Olafsson IH, Ghatan PH, Bro Skejo HP, Hansson LO, Wanecek M et al (2011) Secondary insults following traumatic brain injury enhance complement activation in the human brain and release of the tissue damage marker S100B. Acta Neurochir (Wien) 153:90–100

    Article  Google Scholar 

  48. Unden J, Astrand R, Waterloo K, Ingebrigtsen T, Bellner J, Reinstrup P et al (2007) Clinical significance of serum S100B levels in neurointensive care. Neurocrit Care 6:94–99

    Article  PubMed  CAS  Google Scholar 

  49. Olivecrona M, Rodling-Wahlstrom M, Naredi S, Koskinen LO (2009) S-100B and neuron specific enolase are poor outcome predictors in severe traumatic brain injury treated by an intracranial pressure targeted therapy. J Neurol Neurosurg Psychiatry 80:1241–1247

    Article  PubMed  CAS  Google Scholar 

  50. Pelinka LE, Toegel E, Mauritz W, Redl H (2003) Serum S 100 B: a marker of brain damage in traumatic brain injury with and without multiple trauma. Shock 19:195–200

    Article  PubMed  CAS  Google Scholar 

  51. Bechtel K, Frasure S, Marshall C, Dziura J, Simpson C (2009) Relationship of serum S100B levels and intracranial injury in children with closed head trauma. Pediatrics 124:e697–e704

    Article  PubMed  Google Scholar 

  52. Berger RP, Adelson PD, Pierce MC, Dulani T, Cassidy LD, Kochanek PM (2005) Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J Neurosurg 103:61–68

    PubMed  Google Scholar 

  53. Castellani C, Bimbashi P, Ruttenstock E, Sacherer P, Stojakovic T, Weinberg AM (2009) Neuroprotein s-100B—a useful parameter in paediatric patients with mild traumatic brain injury? Acta Paediatr 98:1607–1612

    Article  PubMed  CAS  Google Scholar 

  54. Castellani C, Stojakovic T, Cichocki M, Scharnagl H, Erwa W, Gutmann A et al (2008) Reference ranges for neuroprotein S-100B: from infants to adolescents. Clin Chem Lab Med 46:1296–1299

    Article  PubMed  CAS  Google Scholar 

  55. Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E et al (1999) S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56:338–344

    Article  PubMed  CAS  Google Scholar 

  56. Hauschild A, Michaelsen J, Brenner W, Rudolph P, Glaser R, Henze E et al (1999) Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 9:155–161

    Article  PubMed  CAS  Google Scholar 

  57. Molina R, Navarro J, Filella X, Castel T, Ballesta AM (2002) S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol 23:39–44

    Article  PubMed  CAS  Google Scholar 

  58. Petzold A, Jenkins R, Watt HC, Green AJ, Thompson EJ, Keir G et al (2003) Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer’s disease. Neurosci Lett 336:167–170

    Article  PubMed  CAS  Google Scholar 

  59. Rothermundt M, Peters M, Prehn JH, Arolt V (2003) S100B in brain damage and neurodegeneration. Microsc Res Tech 60:614–632

    Article  PubMed  CAS  Google Scholar 

  60. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE (2009) Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia–original research and meta-analysis. Psychiatry Res 167:66–72

    Article  PubMed  CAS  Google Scholar 

  61. Beer C, Blacker D, Bynevelt M, Hankey GJ, Puddey IB (2010) Systemic markers of inflammation are independently associated with S100B concentration: results of an observational study in subjects with acute ischaemic stroke. J Neuroinflammation 7:71

    Article  PubMed  Google Scholar 

  62. Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ (2001) Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer’s disease. Neurochem Int 39:409–413

    Article  PubMed  CAS  Google Scholar 

  63. Chaves ML, Camozzato AL, Ferreira ED, Piazenski I, Kochhann R, Dall’Igna O et al (2010) Serum levels of S100B and NSE proteins in Alzheimer’s disease patients. J Neuroinflammation 7:6

    Article  PubMed  Google Scholar 

  64. Gruden MA, Davidova TB, Malisauskas M, Sewell RD, Voskresenskaya NI, Wilhelm K et al (2007) Differential neuroimmune markers to the onset of Alzheimer’s disease neurodegeneration and dementia: autoantibodies to Abeta((25-35)) oligomers, S100b and neurotransmitters. J Neuroimmunol 186:181–192

    Article  PubMed  CAS  Google Scholar 

  65. Mitosek-Szewczyk K, Gordon-Krajcer W, Flis D, Stelmasiak Z (2011) Some markers of neuronal damage in cerebrospinal fluid of multiple sclerosis patients in relapse. Folia Neuropathol 49:191–196

    PubMed  CAS  Google Scholar 

  66. Rothermundt M, Ahn JN, Jorgens S (2009) S100B in schizophrenia: an update. Gen Physiol Biophys 28 Spec No Focus:F76–F81

    PubMed  Google Scholar 

  67. Muller K, Elverland A, Romner B, Waterloo K, Langbakk B, Unden J et al (2006) Analysis of protein S-100B in serum: a methodological study. Clin Chem Lab Med 44:1111–1114

    Article  PubMed  CAS  Google Scholar 

  68. Alber B, Hein R, Garbe C, Caroli U, Luppa PB (2005) Multicenter evaluation of the analytical and clinical performance of the Elecsys S100 immunoassay in patients with malignant melanoma. Clin Chem Lab Med 43:557–563

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

    Ramona Astrand & Bertil Romner

  2. Department of Anesthesiology and Intensive Care, Skane University Hospital, Malmoe, Sweden

    Johan Undén

Authors
  1. Ramona Astrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johan Undén
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bertil Romner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bertil Romner .

Editor information

Editors and Affiliations

  1. Div of Clinical Chem & Biochem, Department of Pediatrics, University of Zürich, Steinwiesstrasse 75, Zürich, 8032, Switzerland

    Claus W. Heizmann

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this protocol

Cite this protocol

Astrand, R., Undén, J., Romner, B. (2013). Clinical Use of the Calcium-Binding S100B Protein. In: Heizmann, C. (eds) Calcium-Binding Proteins and RAGE. Methods in Molecular Biology, vol 963. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-230-8_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-230-8_23

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-229-2

  • Online ISBN: 978-1-62703-230-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation